Clinical Trials Using Blinatumomab

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest

Clinical trials are research studies that involve people. The clinical trials on this list are studying Blinatumomab. All trials on the list are supported by NCI.

NCI’s basic information about clinical trials explains the types and phases of trials and how they are carried out. Clinical trials look at new ways to prevent, detect, or treat disease. You may want to think about taking part in a clinical trial. Talk to your doctor for help in deciding if one is right for you.

Trials 1-16 of 16
  • Combination Chemotherapy with or without Blinatumomab in Treating Patients with Newly Diagnosed BCR-ABL-Negative B Lineage Acute Lymphoblastic Leukemia

    This randomized phase III trial studies combination chemotherapy with blinatumomab to see how well it works compared to induction chemotherapy alone in treating patients with newly diagnosed breakpoint cluster region (BCR)-c-abl oncogene 1, non-receptor tyrosine kinase (ABL)-negative B lineage acute lymphoblastic leukemia. Drugs used in chemotherapy work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Monoclonal antibodies, such as blinatumomab, may block cancer growth in different ways by targeting certain cells. It is not yet known whether combination chemotherapy is more effective with or without blinatumomab in treating newly diagnosed acute lymphoblastic leukemia.
    Location: 422 locations

  • Blinatumomab in Treating Younger Patients with Relapsed B-cell Acute Lymphoblastic Leukemia

    This randomized phase III trial studies how well blinatumomab works compared with standard combination chemotherapy in treating patients with B-cell acute lymphoblastic leukemia that has returned after a period of improvement (relapsed). Monoclonal antibodies, such as blinatumomab, may interfere with the ability of tumor cells to grow and spread. It is not yet known whether standard combination chemotherapy is more effective than blinatumomab in treating relapsed B-cell acute lymphoblastic leukemia.
    Location: 158 locations

  • Blinatumomab and Combination Chemotherapy or Dasatinib, Prednisone, and Blinatumomab in Treating Older Patients with Acute Lymphoblastic Leukemia

    This phase II trial studies the side effects and how well blinatumomab and combination chemotherapy or dasatinib, prednisone, and blinatumomab work in treating older patients with acute lymphoblastic leukemia. Monoclonal antibodies, such as blinatumomab, find cancer cells and help kill them. Drugs used in chemotherapy, such as prednisone, vincristine sulfate, methotrexate, and mercaptopurine, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Dasatinib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Giving blinatumomab with combination chemotherapy or dasatinib and prednisone may kill more cancer cells.
    Location: 179 locations

  • Lenalidomide and Blinatumomab in Treating Patients with Relapsed Non-Hodgkin Lymphoma

    This phase I trial studies the side effects and best dose of lenalidomide and blinatumomab when given together in treating patients with non-Hodgkin lymphoma that has returned after a period of improvement. Biological therapies, such as lenalidomide and blinatumomab, use substances made from living organisms that may stimulate or suppress the immune system in different ways and stop cancer cells from growing.
    Location: 13 locations

  • Blinatumomab and Nivolumab with or without Ipilimumab in Treating Patients with Poor-Risk Relapsed or Refractory CD19+ Precursor B-Lymphoblastic Leukemia

    This phase I trial studies the side effects and best dose of blinatumomab when given with nivolumab alone or nivolumab and ipilimumab in treating patients with poor-risk CD19+ precursor B-lymphoblastic leukemia that has come back after a period of improvement or has not responded to treatment. Monoclonal antibodies, such as blinatumomab, nivolumab and ipilimumab, may interfere with the ability of tumor cells to grow and spread.
    Location: 5 locations

  • Blinatumomab after Stem Cell Transplant in Treating Patients with Diffuse Large B-cell Lymphoma or Transformed Large Cell Lymphoma

    This pilot phase I trial studies how well blinatumomab works after stem cell transplant in treating patients with diffuse large B-cell lymphoma or transformed large cell lymphoma. Monoclonal antibodies, such as blinatumomab, may block cancer growth in different ways by targeting certain cells and improve response to the transplant.
    Location: Siteman Cancer Center at Washington University, Saint Louis, Missouri

  • Ibrutinib and Blinatumomab in Treating Patients with Relapsed or Refractory B Acute Lymphoblastic Leukemia

    This phase II trial studies how well ibrutinib and blinatumomab work in treating patients with B acute lymphoblastic leukemia that has come back or is not responding to treatment. Ibrutinib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Monoclonal antibodies, such as blinatumomab, may interfere with the ability of cancer cells to grow and spread. Giving ibrutinib and blinatumomab may work better in treating patients with relapsed or refractory B acute lymphoblastic leukemia.
    Location: University of California Davis Comprehensive Cancer Center, Sacramento, California

  • A Phase 1b Open-Label Study Investigating the Safety and Pharmacokinetics of Administration of Subcutaneous Blinatumomab for the Treatment of Relapsed / Refractory Indolent Non-Hodgkin's Lymphoma

    Primary Objective: • To evaluate the safety and tolerability of every 12 hours (q12h) and every 24 hours (q24h) administration of subcutaneous (SC) blinatumomab Secondary Objectives: - To determine pharmacokinetics (PK) with continuous intravenous (cIV) and SC administrations - To estimate the maximum tolerated dose (MTD) tested for blinatumomab administered subcutaneously - To determine the incidence of anti-blinatumomab antibody formation following SC administration - To evaluate efficacy response following treatment with SC blinatumomab administration Exploratory Objective: - To determine the pharmacodynamics (PD) time profiles for B-and T-lymphocytes as well as cytokine profiles during SC administration - To evaluate efficacy response following treatment with SC blinatumomab administration using Lugano criteria
    Location: City of Hope Comprehensive Cancer Center, Duarte, California

  • Study to Evaluate Safety and Efficacy of Blinatumomab in Subjects With Relapsed / Refractory (R / R) Aggressive B-Cell NHL

    This is a phase 2 / 3 open label, multicenter trial testing blinatumomab monotherapy for the treatment of subjects with Relapsed / Refractory (R / R) aggressive B-NHL not achieving CMR after 2 cycles of standard platinum-based chemotherapy regimens administered as S1. This study incorporates multiple interim analyses for futility, efficacy, and unblinded sample-size re-estimation. In the phase 3 part of the study, blinatumomab will be compared to Investigator's Choice chemotherapy.
    Location: 2 locations

  • Blinatumomab and Combination Chemotherapy as Frontline Therapy in Treating Patients with B Acute Lymphoblastic Leukemia

    This phase II trial studies how well blinatumomab and combination chemotherapy work as frontline therapy in treating patients with B acute lymphoblastic leukemia. Monoclonal antibodies, such as blinatumomab, may interfere with the ability of cancer cells to grow and spread. Drugs used in chemotherapy, such as cyclophosphamide, vincristine sulfate, doxorubicin hydrochloride, dexamethasone, cytarabine, mercaptopurine, methotrexate, and prednisone work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving blinatumomab and combination chemotherapy may work better in treating patients with B acute lymphoblastic leukemia.
    Location: M D Anderson Cancer Center, Houston, Texas

  • Blinatumomab in Treating Patients with Relapsed or Refractory Non-Hodgkin Lymphoma

    This phase II trial studies how well blinatumomab works in treating patients with non-Hodgkin lymphoma that has come back or has not responded to treatment. Monoclonal antibodies, such as blinatumomab, may interfere with the ability of cancer cells to grow and spread.
    Location: Massachusetts General Hospital, Charlestown, Massachusetts

  • Blinatumomab after Donor Stem Cell Transplant in Treating Patients with Acute Lymphoblastic Leukemia

    This phase II trial studies how well blinatumomab works as maintenance therapy after donor stem cell transplant in treating patients with acute lymphoblastic leukemia. Monoclonal antibodies, such as blinatumomab, may interfere with the ability of cancer cells to grow and spread.
    Location: M D Anderson Cancer Center, Houston, Texas

  • Blinatumomab and T Cell Depleted Donor Blood Cell Transplant in Treating Younger Patients with Relapsed or Refractory Hematologic Malignancy after a Previous Transplant

    This phase II trial studies how well blinatumomab and T cell depleted donor blood cell transplant work in treating children and young adults with hematologic cancer that has not responded or has come back after a previous transplant. White blood cells from donors may be able to kill cancer cells in patients with hematologic cancer. Sometimes the transplanted cells from a donor can make an immune response against the body's normal cells (called graft-versus-host disease). Removing the T cells from the donor cells before the transplant may stop this from happening. Monoclonal antibodies, such as blinatumomab, may interfere with the ability of cancer cells to grow and spread. Giving blinatumomab after a blood cell transplant may destroy any remaining cancer cells.
    Location: St. Jude Children's Research Hospital, Memphis, Tennessee

  • Blinatumomab in Treating Patients with B-cell Acute Lymphoblastic Leukemia with Minimal Residual Disease

    This phase II trial studies how well blinatumomab works in treating patients with B-cell acute lymphoblastic leukemia whose disease is in remission (causes no symptoms or signs) but is still present in a small number of cells in the body (minimal residual disease). Blinatumomab is a type of drug called a monoclonal antibody, and may block cancer growth by attaching to certain immune cells and activating them to attack cancer cells.
    Location: M D Anderson Cancer Center, Houston, Texas

  • Inotuzumab Ozogamicin and Combination Chemotherapy in Treating Older Patients with Previously Untreated Acute Lymphoblastic Leukemia

    This phase I / II trial studies the side effects and best dose of inotuzumab ozogamicin and to see how well it works when given together with combination chemotherapy in treating older patients with previously untreated acute lymphoblastic leukemia. Monoclonal antibodies, such as inotuzumab ozogamicin and blinatumomab, can block cancer growth by blocking the ability of cancer cells to grow and spread. Drugs used in chemotherapy work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving inotuzumab ozogamicin together with combination chemotherapy may be a better treatment for acute lymphoblastic leukemia.
    Location: M D Anderson Cancer Center, Houston, Texas

  • Blinatumomab, Pembrolizumab, and Methotrexate in Treating Patients with Relapsed or Refractory CD19 Positive B Acute Lymphoblastic Leukemia

    This phase I / II trial studies how well blinatumomab and pembrolizumab work in treating patients with CD19 positive B acute lymphoblastic leukemia that has come back or does not respond to treatment. Monoclonal antibodies, such as blinatumomab and pembrolizumab, may interfere with the ability of cancer cells to grow and spread. Drugs used in the chemotherapy, such as methotrexate, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving blinatumomab, pembrolizumab, and methotrexate may work better in treating patients with CD19 positive B acute lymphoblastic leukemia.
    Location: 3 locations